

Pharmaceutical Pricing: The South African Experience

Dr Anban Pillay
Cluster Manager: Health Economics
Ministry of Health



DEPARTMENT OF HEALTH
Republic of South Africa

Overview

Healthcare challenges facing South Africa in 1994

Interventions to reduce medicine prices

Impact of pricing regulations



DEPARTMENT OF HEALTH
Republic of South Africa

Pharmaceutical Sector in 1994

Public Sector

- Serves 38 million people
- Mainly essential drugs supplied
- 70% (volume) of medicine sales
- Medicine budget – R3billion
- Income based user fees – free to special groups
- < 50% of pharmacists work in the public sector serving 80% of population


Private Sector

- Essentially insured population – 7million
- All registered drugs available
- 30% (volume) of medicine sales
- Medicine budget – R13billion
- High premiums – unaffordable
- Most pharmacists work in the private sector serving 20% of population

Context: Healthcare Financing, 2006

**Serves 39
m**

R1330pp




**Serves 7 m
= R9428pp**




Source: CMS and Treasury

Pricing Survey- (WHO/HAI)

Amoxicillin 250mg 500's



State Tender System



Overview

Healthcare challenges facing South Africa in 1994

Interventions to reduce medicine prices

Impact of pricing regulations



DEPARTMENT OF HEALTH
Republic of South Africa

Development of a National Drug Policy in 1996

- Generic substitution policy
- Establishment of pricing committee
- Single exit price for medicines
- Fixed fee for wholesalers
- Fixed fee for pharmacists
- Transparent pricing system
- No volume discounts, rebates or bonuses (18A)
- International benchmarking
- Reference pricing
- Pharmacoeconomics



Generic Substitution Policy

- Quality – assessed by medicine registration authority
- COMPETITIVE local manufacturing sector CRUCIAL
- Generic prices – 20-70% lower than patented drug price.
Fast Track registration for essential medicines.
- Generic substitution – “mechanism important”
 - SA, Canada – mandatory
 - Sweden, Germany – prescriber authorisation

Establishment of a Pricing Committee

- Minister appoints members
- Membership – DTI, Finance, Competition Commission, Pharmacists, Law, Consumer, Academics. No industry representation.
- Recommendations to Minister
- Secretariat - Pricing Unit in the Department of Health

Single exit price for medicines

- ***Removal of rebates and discounts***
- Manufacturers sell at a single price irrespective of volumes
- No rebates, discounts or any other perversity
- Maximum price valid for a year
- Logistics fees must be transparent



Fee for Wholesalers

- Definition of logistics services
- Contracts between logistics providers and manufacturers
- Establishment of buying groups-CLAW BACK
- Differences between wholesalers and distributors



Fee for Pharmacists

- 26%/R26 – challenged by the retail pharmacy sector.
- Con. Court – review of the fee but upheld right to regulate.
- Request for information from retailers and other parties.
- Four tier fee structure – open for comment
- Review of comments
- Finalisation of recommendations for ministers consideration
- Gazetting of the fee



Transparent Pricing System

- Printing of price on package
- Invoice to differentiate between SEP and price paid by patient
- Establishment of a website to access medicine prices
- Predictable price of a medicine throughout supply chain



International benchmarking (Originator)

- Basket of five countries
- Lowest price in the basket
- Average exchange rate in basket of countries
- Draft methodology published for comment.



Reference Pricing

Limits the price of an individual drug by comparison with the price of other drugs.

Basis for comparison:

- Same active ingredient
- Drugs in a pharmacological class
- Drugs with similar therapeutic effect

Most effective when there is a strong generics industry.

New drugs in the same pharmacological class/therapeutic class will be referenced using pharmacoeconomics.



Pharmacoeconomic Analyses

Pharmacoeconomics/ cost effectiveness analysis

Evidence based approach

Comparative effectiveness

Comparative safety

Direct and indirect costs

This method rewards true innovation – widely used in many countries.



Overview

Healthcare challenges facing South Africa in 1994


Interventions to reduce medicine prices

Impact of pricing regulations



DEPARTMENT OF HEALTH
Republic of South Africa

Split between Generics vs Original medicines units – 5 Year trend



IMS SANDS TPM data as at Jan 2007 (SANDS: South African National Database)

Impact of pricing regulations

Generic substitution policy

- increased generic substitution – in excess of 30% utilisation
- greater incentive to introduce generics
- transfer of perversity from “Dr’s pen” to “pharmacist”

Pricing committee

- Attacks on the committee – media, lobbying etc
- Court challenges – technical and procedural
- appoint independent committee – technically competent
- no “stakeholder” representation
- technically competent secretariat
- Role of DTI, National Treasury



Impact of pricing regulations

Single exit price/ no rebates, discounts or bonuses

- No price discrimination between rural and urban
- Chain groups will not be able to access bulk discounts
- Reduction of medicine prices – average 19%
- Generics reduced by 25-30%
- Originators reduced by 12%
- Same unit price for different pack sizes – prevent risk transfer

Transparent pricing system

- Greater focus on price – more informed consumer – website, price on pack
- Price competition between manufacturers especially generics
- Pressure on supply chain margins – wholesaler/pharmacy



Impact of pricing regulations

Fixed fee for wholesalers


- Introduced logistics fee – “gaming” in absence of new fixed fee
- Wholesalers – buy drug and on sell – higher cost
- Distributors – no ownership – logistics services
- Wholesalers – generic distribution – efficiency??

Fixed fee for pharmacists


- Pharmacists do supply cost data
- Challenge fee in court
- Markups of 35–40% requested
- 4 tier fee structure – higher % markup for generics



% Annual Average Price Increase



Trends in Total Benefits Paid, 1997 - 2005



- ◆ General Practitioners
- ◆ Dentists
- ◆ Provincial Hospitals
- ◆ Medicines
- ◆ Ex-Gratia Payments
- ◆ Capitated Primary Care
- ◆ Medical Specialists
- ◆ Dental Specialists
- ◆ Private Hospitals
- ◆ Supplementary and Allied Health Professionals
- ◆ Other Benefits

Source: Council for Medical Schemes

Overview

Healthcare challenges facing South Africa in 1994

Interventions to reduce medicine prices

Impact of pricing regulations

Towards a National Health Insurance



DEPARTMENT OF HEALTH
Republic of South Africa

How we get the uncovered covered?




DEPARTMENT OF HEALTH
Republic of South Africa

Policy Objectives

1. The removal of unfair access barriers to health insurance cover for low income groups
2. The achievement of a reasonable and equitable system of cross subsidies across all income groups





BBP = Basic Benefit Package (i.e. a comprehensive essential package of healthcare benefits)

TES = Tax Expenditure Subsidies (both employer and individual subsidies)

PMBs = Prescribed Minimum Benefits (current legal requirement, which is not fully comprehensive)

Concluding Remarks

- Price regulation is an effective intervention
- One size does not fit all
- Political commitment
- Regulator will always play “catch up”



Thank You



DEPARTMENT OF HEALTH
Republic of South Africa